Kong Heidi H, Fine Howard A, Stern Jere B, Turner Maria L Chanco
Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bldg 10, Room 12N238, 10 Center Dr, Bethesda, MD 20892, USA.
Arch Dermatol. 2009 Aug;145(8):923-5. doi: 10.1001/archdermatol.2009.177.
Photosensitivity has been reported in patients who were treated with vandetanib (ZD6474), an inhibitor of epidermal growth factor receptor, vascular endothelial growth factor receptor, and the RET (rearranged during transfection) kinases.
We describe the occurrence of cutaneous hyperpigmentation after photosensitivity in 2 patients who were treated with vandetanib. The pigmentation patterns were variable within and between patients. Biopsy specimens from different sites revealed variability in Perls and Fontana staining patterns.
These 2 cases highlight the unusual occurrence of cutaneous hyperpigmentation after vandetanib-associated photosensitivity, a reaction that demonstrates that medications are important causes of acquired photosensitivity and hyperpigmentation. Aggressive photoprotection may facilitate the resolution of diffuse hyperpigmentation. Dermatologists should endeavor to identify and report novel cutaneous adverse effects as new targeted therapies are developed.
有报道称，接受凡德他尼（ZD6474）治疗的患者出现了光敏反应。凡德他尼是一种表皮生长因子受体、血管内皮生长因子受体和RET（转染期间重排）激酶的抑制剂。
我们描述了2例接受凡德他尼治疗的患者在出现光敏反应后发生皮肤色素沉着过度的情况。患者内部和患者之间的色素沉着模式各不相同。不同部位的活检标本显示普鲁士蓝染色和Fontana染色模式存在差异。
这2例病例突出了凡德他尼相关光敏反应后出现皮肤色素沉着过度这一不寻常情况，这种反应表明药物是获得性光敏反应和色素沉着过度的重要原因。积极的光防护可能有助于弥漫性色素沉着过度的消退。随着新的靶向治疗方法的开发，皮肤科医生应努力识别和报告新的皮肤不良反应。
